Naveen Pemmaraju: CK0801 in Treatment of Bone Marrow Failure Syndromes

Naveen Pemmaraju posted on X about recent paper by Tapan M. Kadia et al., commenting:

“Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes | NEJM Evidence ||”

Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes

Journal: NEJM Evidence

Author: Tapan M. Kadia, Meixian Huang, Naveen Pemmaraju, Hussein A. Abbas,  Christopher Ly, Lucia Masarova, Musa Yilmaz, Mi-Ae Lyu, Ke Zeng, Tara Sadeghi, Robin Cook, Courtney D. DiNardo, Naval Daver, Ghayas C. Issa, Elias Jabbour, Gautam Borthakur, Nitin Jain, Guillermo Garcia-Manero, Simrit Parmar, Christopher Flowers, Hagop Kantarjian and Srdan Verstovsek.

Source: Naveen Pemmaraju/X

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.